 Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
| Descriptor ID |
D019005
|
| MeSH Number(s) |
D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 4 | 1 | 5 | | 2003 | 1 | 2 | 3 | | 2004 | 5 | 3 | 8 | | 2005 | 1 | 1 | 2 | | 2006 | 5 | 3 | 8 | | 2007 | 5 | 3 | 8 | | 2008 | 3 | 3 | 6 | | 2009 | 7 | 1 | 8 | | 2010 | 3 | 1 | 4 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 4 | 0 | 4 | | 2014 | 4 | 2 | 6 | | 2015 | 6 | 1 | 7 | | 2016 | 4 | 6 | 10 | | 2017 | 4 | 4 | 8 | | 2018 | 11 | 3 | 14 | | 2019 | 7 | 9 | 16 | | 2020 | 10 | 6 | 16 | | 2021 | 12 | 10 | 22 | | 2022 | 10 | 16 | 26 | | 2023 | 1 | 21 | 22 | | 2024 | 8 | 2 | 10 | | 2025 | 12 | 11 | 23 | | 2026 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Calton MA, Croze RH, Sullivan TH, Collins SA, Tucker S, Whittlesey KJ, Kim DH, Nye JA, Beliakoff G, Quezada M, Burns C, Schmitt C, Klein A, Jia V, Kovacs L, Lauko D, Yoh K, Nguyen K, Barglow K, Gonzales J, Khoday D, Mason T, Delaria K, Bashour K, Kotterman M, Schaffer D, Song A, Francis P, Taylor-Cousar JL, Kirn D. Design and characterization of 4D-710, an aerosolized gene therapy for cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2026 Jul 01; 74(7):837-846.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Zemanick ET, Somayaji R. Clearing the Air: Rethinking Airway Infection With CFTR Modulators. J Infect Dis. 2026 04 29; 233(4):628-630.
-
Kroes S, Taylor-Cousar JL, Zampoli M, Karadag B, van der Ent CK, de Winter-de Groot KM, Beekman JM, Spelier S. Patient-Derived Intestinal Organoids in the Global Cystic Fibrosis Landscape. Pediatr Pulmonol. 2026 Apr; 61(4):e71584.
-
Lee J, Yekula A, Wexler A, Zhuang W, Elangovan A, Rosario J, Burger P, Ramaraju G, Addissie B, Lim N, Narkewicz MR, Twohig P. Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease. World J Gastroenterol. 2026 Mar 14; 32(10):114946.
-
Metcalf A, Hoppe JE, Martiniano SL, Zaretsky MV, Zemanick ET, Sagel SD. In Utero CFTR Modulator Therapy in Fetuses With Cystic Fibrosis. Neoreviews. 2026 Mar 01; 27(3):e157-e169.
-
Zaretsky MV, Blumenfeld YJ, Szentpetery SS, Taylor-Cousar JL. Translating Emerging Data for Fetal Treatment of Cystic Fibrosis. Prenat Diagn. 2026 Mar; 46(3):417-423.
-
Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, Ramsey B, Taylor-Cousar JL, McKone EF, Tullis E, Weinstock TG, Tan V, Ahluwalia N, Mahic M, Liu L, Saayman S, Altshuler D, Waltz D, Mall MA, Fajac I. Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. Am J Respir Crit Care Med. 2026 02 01; 212(2):327-337.
-
Shirley Bezerra M, Zemel BS, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Chan CL, Kelly A. Longitudinal changes in bone mineral density after initiation of elexacaftor-tezacaftor-ivacaftor in youth and adults with cystic fibrosis: PROMISE-ENDO. J Cyst Fibros. 2026 May; 25(3):457-465.
-
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F. Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros. 2026 May; 25(3):450-456.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|